Back to today’s briefing

Story perspectives

Moderna’s Flu Vaccine Outperforms Traditional Shots by 26.6%

7/2/2025

47 3

Summary

Story summary

Moderna's mRNA-1010 flu vaccine has shown remarkable promise, boasting a 26.6% higher efficacy than traditional flu vaccines in adults aged 50 and above during a Phase 3 trial with over 40,000 participants across 11 countries. Excitingly, Moderna is set to unveil these groundbreaking results at an upcoming medical conference while pursuing regulatory approval.

1 of 1

Story summary

Moderna's mRNA-1010 flu vaccine has shown remarkable promise, boasting a 26.6% higher efficacy than traditional flu vaccines in adults aged 50 and above during a Phase 3 trial with over 40,000 participants across 11 countries. Excitingly, Moderna is set to unveil these groundbreaking results at an upcoming medical conference while pursuing regulatory approval.